Therefore, the treatment response and prognosis of DE-DLBCL patients with p53 expression >50% are poorer; however, the ZR-CHOP regimen can assist these patients in achieving earlier CR and significantly enhancing both CRR and PFS. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.